Review and re-appraisal of patients treated with splenectomy for immune thrombocytopenic purpura at five years and beyond

The risk of pneumococcal infection post splenectomy is life long so all patients undergoing splenectomy are given polyvalent (23-valent) unconjugated pneumococcal polysaccharide vaccine, preoperatively. The aim of this study was 1. to measure the success of splenectomy at a tertiary institution at 5 years and beyond. 2. To review the incidence of complications peri-operatively and long term. 3. Review the need for possible re-vaccination (as recommended in American and British guidelines and 4. perform a re-appraisal of patients found to be refractory to treatment.

Grantor dc:publisher.institution

Division of Clinical Haematology

Year dc:date.issued

2002

Author dc:creator

• Seth, Yunus S

Advisor dc:contributor.advisor

• Novitzky, Nicholas

Language dc:language.iso

eng

Handle dc:identifier.uri

http://hdl.handle.net/11427/2833

OAI identifier oai:identifier

oai:open.uct.ac.za:11427/2833